Ulticure Biolabs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-12-2024
- Paid Up Capital ₹ 0.10 M
as on 09-12-2024
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.99 M
as on 09-12-2024
- Revenue 2.64%
(FY 2019)
- Profit -76.11%
(FY 2019)
- Ebitda -73.25%
(FY 2019)
- Net Worth
- Total Assets -11.79%
(FY 2019)
About Ulticure Biolabs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.99 M.
Jitendra Pathak and Kiran Pathak serve as directors at the Company.
- CIN/LLPIN
U51909DL2012PTC237931
- Company No.
237931
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jun 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ulticure Biolabs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendra Pathak  | Director | 22-Jun-2012 | Current |
| Kiran Pathak | Director | 22-Jun-2012 | Current |
Financial Performance and Corporate Structure Insights of Ulticure Biolabs.
Ulticure Biolabs Private Limited, for the financial year ended 2019, experienced modest growth in revenue, with a 2.64% increase. The company also saw a substantial fall in profitability, with a 76.11% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ulticure Biolabs?
In 2019, Ulticure Biolabs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Humed Medicines Private LimitedActive 8 years 9 monthsJitendra Pathak and Kiran Pathak are mutual person
- Rajsi Services Private LimitedActive 3 years 2 months
Jitendra Pathak and Kiran Pathak are mutual person
- Radhey Rani Services Private LimitedActive 2 years 26 days
Jitendra Pathak and Kiran Pathak are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Andhra Bank Creation Date: 18 Sep 2012 | ₹0.99 M | Open |
How Many Employees Work at Ulticure Biolabs?
Unlock and access historical data on people associated with Ulticure Biolabs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ulticure Biolabs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ulticure Biolabs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
